The efficacy and safety of cryoprecipitate in the treatment of acquired hypofibrinogenaemia.
Acquired hypofibrinogenaemia can result in haemorrhage and significant morbidity and mortality.
Cryoprecipitate is well established as the treatment of acquired hypofibrinogenaemia in the UK. Although its use is being superseded by fibrinogen concentrate in a number of other countries (Warmuth et al, 2012), there remains a paucity of clinical data on the relative merits of both products, leading to significant variation in clinical practice between institutions (Tinegate et al, 2012; Wikkelsø et al, 2013;) This retrospective, non?controlled observational study aimed to determine the safety and efficacy of cryoprecipitate in improving plasma fibrinogen levels, coagulation parameters and clinical status in acute and chronic acquired hypofibrinogenaemia.